Downregulation of PHLPP Expression Contributes to Hypoxia-induced Resistance to Chemotherapy in Colon Cancer Cells

Overview

Journal Mol Cell Biol

Specialty Cell Biology

Date 2013 Sep 25

PMID 24061475

Citations 31

Authors

Yang-An Wen

Payton D Stevens

Michael L Gasser

Romina Andrei

Tianyan Gao

Affiliations

Soon will be listed here.

Abstract

Hypoxia is a feature of solid tumors. Most tumors are at least partially hypoxic. This hypoxic environment plays a critical role in promoting resistance to anticancer drugs. PHLPP, a novel family of Ser/Thr protein phosphatases, functions as a tumor suppressor in colon cancers. Here, we show that the expression of both PHLPP isoforms is negatively regulated by hypoxia/anoxia in colon cancer cells. Interestingly, a hypoxia-induced decrease of PHLPP expression is attenuated by knocking down HIF1α but not HIF2α. Whereas the mRNA levels of PHLPP are not significantly altered by oxygen deprivation, the reduction of PHLPP expression is caused by decreased protein translation downstream of mTOR and increased degradation. Specifically, hypoxia-induced downregulation of PHLPP is partially rescued in TSC2 or 4E-BP1 knockdown cells as the result of elevated mTOR activity and protein synthesis. Moreover, oxygen deprivation destabilizes PHLPP protein by decreasing the expression of USP46, a deubiquitinase of PHLPP. Functionally, downregulation of PHLPP contributes to hypoxia-induced chemoresistance in colon cancer cells. Taken together, we have identified hypoxia as a novel mechanism by which PHLPP is downregulated in colon cancer, and the expression of PHLPP may serve as a biomarker for better understanding of chemoresistance in cancer treatment.

Citing Articles

MiR-25-3p regulates pulmonary arteriovenous malformation after Glenn procedure in patients with univentricular heart via the PHLPP2-HIF-1α axis.

Kawamura J, Yamakuchi M, Ueno K, Hashiguchi T, Okamoto Y Sci Rep. 2025; 15(1):4138.

PMID: 39900983 PMC: 11790876. DOI: 10.1038/s41598-025-88840-5.

Protein serine/threonine phosphatases in tumor microenvironment: a vital player and a promising therapeutic target.

Liu Y, Xia F, Zhu C, Song J, Tang B, Zhang B Theranostics. 2025; 15(3):1164-1184.

PMID: 39776803 PMC: 11700861. DOI: 10.7150/thno.104529.

Role of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy.

Song C, Kim H, Kim M, Park H, Paek S, Terezakis S Cancer Res Treat. 2024; 57(1):1-10.

PMID: 38853541 PMC: 11729307. DOI: 10.4143/crt.2024.255.

Comprehensive analysis of the role of ubiquitin-specific peptidases in colorectal cancer: A systematic review.

Al-Balushi E, Al Marzouqi A, Tavoosi S, Baghsheikhi A, Sadri A, Sharifi Aliabadi L World J Gastrointest Oncol. 2024; 16(1):197-213.

PMID: 38292842 PMC: 10824112. DOI: 10.4251/wjgo.v16.i1.197.

Hypoxia-inducible factors: master regulators of hypoxic tumor immune escape.

Wu Q, You L, Nepovimova E, Heger Z, Wu W, Kuca K J Hematol Oncol. 2022; 15(1):77.

PMID: 35659268 PMC: 9166526. DOI: 10.1186/s13045-022-01292-6.

References

Li X, Stevens P, Yang H, Gulhati P, Wang W, Evers B . The deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancer. Oncogene. 2012; 32(4):471-8. PMC: 3371166. DOI: 10.1038/onc.2012.66. View

Baba Y, Nosho K, Shima K, Irahara N, Chan A, Meyerhardt J . HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol. 2010; 176(5):2292-301. PMC: 2861094. DOI: 10.2353/ajpath.2010.090972. View

Gao T, Furnari F, Newton A . PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell. 2005; 18(1):13-24. DOI: 10.1016/j.molcel.2005.03.008. View

Keith B, Johnson R, Simon M . HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011; 12(1):9-22. PMC: 3401912. DOI: 10.1038/nrc3183. View

Shimizu K, MacKenzie S, Storm D . SCOP/PHLPP and its functional role in the brain. Mol Biosyst. 2009; 6(1):38-43. PMC: 3487473. DOI: 10.1039/b911410f. View

Imamura T, Kikuchi H, Herraiz M, Park D, Mizukami Y, Mino-Kenduson M . HIF-1alpha and HIF-2alpha have divergent roles in colon cancer. Int J Cancer. 2008; 124(4):763-71. PMC: 2682346. DOI: 10.1002/ijc.24032. View

Larson Y, Liu J, Stevens P, Li X, Li J, Evers B . Tuberous sclerosis complex 2 (TSC2) regulates cell migration and polarity through activation of CDC42 and RAC1. J Biol Chem. 2010; 285(32):24987-98. PMC: 2915734. DOI: 10.1074/jbc.M109.096917. View

Marshall J . The role of bevacizumab as first-line therapy for colon cancer. Semin Oncol. 2006; 32(6 Suppl 9):S43-7. DOI: 10.1053/j.seminoncol.2005.06.003. View

Majmundar A, Wong W, Simon M . Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010; 40(2):294-309. PMC: 3143508. DOI: 10.1016/j.molcel.2010.09.022. View

10.

Brown J, Wilson W . Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004; 4(6):437-47. DOI: 10.1038/nrc1367. View

11.

Pei H, Li L, Fridley B, Jenkins G, Kalari K, Lingle W . FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell. 2009; 16(3):259-66. PMC: 2755578. DOI: 10.1016/j.ccr.2009.07.016. View

12.

Molina J, Agarwal N, Morales F, Hayashi Y, Aldape K, Cote G . PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. Oncogene. 2011; 31(10):1264-74. PMC: 3208076. DOI: 10.1038/onc.2011.324. View

13.

Qiao M, Wang Y, Xu X, Lu J, Dong Y, Tao W . Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell. 2010; 38(4):512-23. DOI: 10.1016/j.molcel.2010.03.017. View

14.

Erler J, Cawthorne C, Williams K, Koritzinsky M, Wouters B, Wilson C . Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol. 2004; 24(7):2875-89. PMC: 371100. DOI: 10.1128/MCB.24.7.2875-2889.2004. View

15.

Rankin E, Giaccia A . The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ. 2008; 15(4):678-85. PMC: 3050610. DOI: 10.1038/cdd.2008.21. View

16.

DeYoung M, Horak P, Sofer A, Sgroi D, Ellisen L . Hypoxia regulates TSC1/2-mTOR signaling and tumor suppression through REDD1-mediated 14-3-3 shuttling. Genes Dev. 2008; 22(2):239-51. PMC: 2192757. DOI: 10.1101/gad.1617608. View

17.

Cannito S, Novo E, Compagnone A, di Bonzo L, Busletta C, Zamara E . Redox mechanisms switch on hypoxia-dependent epithelial-mesenchymal transition in cancer cells. Carcinogenesis. 2008; 29(12):2267-78. DOI: 10.1093/carcin/bgn216. View

18.

Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007; 26(2):225-39. DOI: 10.1007/s10555-007-9055-1. View

19.

Thoreen C, Chantranupong L, Keys H, Wang T, Gray N, Sabatini D . A unifying model for mTORC1-mediated regulation of mRNA translation. Nature. 2012; 485(7396):109-13. PMC: 3347774. DOI: 10.1038/nature11083. View

20.

Brugarolas J, Lei K, Hurley R, Manning B, Reiling J, Hafen E . Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 2004; 18(23):2893-904. PMC: 534650. DOI: 10.1101/gad.1256804. View